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with filgrastim/lenograstim (0.340, 0.316, 0.410 for TC, AC-T, FEC-D, respectively). 
PP with pegfilgrastim was cost-effective versus SP with pegfilgrastim across all 
chemotherapy schemes (ICERs per FN event avoided: € 7,472, € 18,017 and € 9,996 for 
TC, AC-T and FEC-D, respectively). SP with pegfilgrastim was cost-effective versus 
no prophylaxis. All other treatment strategies were excluded from the analysis via 
extended dominance or were dominated by a less expensive and more effective 
strategy. For instance, PP and SP with lipegfilgrastim was found to be dominated 
by PP and SP with pegfilgrastim.These results held for patients with stage II and III 
BC. ConClusions: Our analysis finds PP with pegfilgrastim to be a cost-effective 
option for chemotherapy-induced FN in patients with BC in Greece.
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objeCtives: To evaluate which strategy for implementing exercise interventions for 
cancer survivors and increasing providers´ adherence to the exercise guidance has 
the highest expected value, using value-of-implementation analysis. Methods: 
The net-benefit framework underpinning health economic evaluations is used to 
conduct a value-of-implementation analysis considering seven implementation 
strategies (ISTs), including continuing medical education (CME), educational out-
reach visits (EOV), educational printed materials (EPM), local opinion leaders (LOPL), 
audit and feedback (AF), reminder systems (RS), and a multifaceted strategy (MF) 
consisting of CME and AF. The analysis consists of four steps; (1) analysing the 
expected value of perfect implementation (EVPIM) (2) assessing the estimated costs 
of the various ISTs, (3) comparing the ISTs´ costs to the EVPIM to decide which of 
these are considered cost-effective, and (4) assessing the total net benefit of the ISTs 
to identify which strategy has the greatest value. Results: The EVPIM for physical 
exercise in the Netherlands is € 522m, which represents the maximum value that 
could be achieved if the guidance was implemented perfectly with a 100% adher-
ence. The costs of the implementation strategies are lowest for PEM with € 710,600 
and highest for MF with € 2,173,700. All ISTs´ costs are well below the EVPIM and thus 
all ISTs are cost-effective. The net-benefit of the ISTs ranges from € 15,753,000 for 
PEM to € 10,150,500 for RS. ConClusions: All evaluated implementation strategies 
are a cost-effective way of implementing physical exercise interventions for cancer 
survivors and increasing health professionals´ adherence to this guideline. However, 
all strategies contribute only marginally to achieving the highest possible value of 
implementation. This suggests that investing in more intensive implementation 
would be justified given the expected net-benefit.
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objeCtives: Overall survival (OS) and other important clinical trial endpoints seem 
increasingly more elusive in supporting rapid and efficient incorporation of innova-
tive cancer drugs in clinical practice. We propose a clinical trial based pharmacoeco-
nomic framework to assess the early therapeutic and economic value of ruxolitinib 
in patients with intermediate-2 or high-risk primary myelofibrosis. Methods: 
Individual level data from patients randomized to ruxolitinib or best available 
therapy (BAT) in the COMFORT-II study was used to estimate: (a) OS, accounting 
for crossover effects, using Rank Preserving Structural Failure Time models; (b) 
treatment benefits beyond normative trial progression endpoints, using treatment 
persistence as a proxy for clinical progression; (c) drug therapy costs considering 
detailed timeline patterns of ruxolitinib dose adjustments, using a piecewise mixed 
regression model for continuous longitudinal data; and (d) the time evolution of the 
average number of red blood cell transfusions per patient, using a mixed regression 
model for ordered multinomial longitudinal data. Results: A 3.3 year increment 
in life expectancy was estimated for ruxolitinib as compared to BAT (HR OS = 0.30; 
[95% CI: 0.17 - 0.55]; p-value < 0.001), resulting in a 2.43 discounted (5%/year) incre-
ment in life years (LY). Corresponding incremental lifetime health care cost amount 
to 97,052€ per patient starting treatment with ruxolitinib. Of those, roughly 90% is 
for drug therapy costs (87,267€ ) with the remaining 9,785€ attributable mainly to 
patients being alive for longer periods and consuming more heath care resources. 
This results in an incremental cost-effectiveness ratio of 40,000€ /LY gained with 
ruxolitinib. A probabilistic sensitivity analysis showed a greater than 95% prob-
ability of ruxolitinib being cost-effective against BAT, at a willingness to pay up 
to 50,000€ /LY. ConClusions: We show how valuable information from clinical 
trials can be used to support informed decisions about the early incorporation of 
innovative drugs.
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objeCtives: The objective of this study is to evaluate cost-effectiveness of pertu-
zumab in combination with trastuzumab and docetaxel for HER2-positive metastatic 
breast cancer in Japan. The National Institute for Health and Care Excellence (NICE) in 
the UK did not recommend pertuzumab due to poorer cost-effectiveness. While the 
Ministry of Health and Welfare of Japan decided to cover pertuzumab by health insur-
ance in 2013, its cost-effectiveness in Japan has not yet been reported. Methods: 
Cost-effectiveness analysis was performed using a Markov model based on clini-
cal data from a phase III randomized double-blind placebo-controlled international 
multicenter clinical trial (CLEOPATRA). Pertuzumab in combination with trastuzumab 
and docetaxel was compared with trastuzumab and docetaxel. The base case was 
of-life cancer drugs, ceritinib may be considered as a cost-effective option compared 
with other available therapies for previous treated ALK+ NSCLC.
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objeCtives: To summarize cost-effectiveness of bortezomib (BTZ) for multi-
ple myeloma (MM) and identify bias in the published cost-effectiveness analysis 
(CEA). Methods: Electronic bibliographic databases were searched from 2003 to 
2014 for eligible CEA. The full publications of included CEAs were reviewed for data 
extraction. The reported base case incremental cost-effectiveness ratio per gained 
quality adjusted life year (QALY) or life year (LY) were converted to the ratio to 2013 
country-specific gross domestic product per capita (GDPPC) to interpret cost-effec-
tiveness according to World Health Organization (WHO) recommendation on cost-
effectiveness threshold (3 GDPPC). The study designs and methods of the included 
CEAs were assessed regarding their impact on cost-effectiveness. Results: 3 CEAs 
reported favourable cost-effectiveness of BTZ as induction treatment prior to stem cell 
transplantation (SCT) in Canada, Poland, and Germany (0.9379 to 2.351 GDPPC/QALY). 
BTZ/melpahlan/prednisone (VMP) was cost-effective compared to MP for MM ineligi-
ble for SCT in Canada, UK, and USA (0.9367 GDPPC to 2.0279 GDPPC/QALY). However, 
the survival outcomes estimated from indirect comparisons for VMP versus thalido-
mide (THD)/MP (MPT) and lenalidomide (LEN)/MP plus LEN as maintenance therapy 
(MPR-R) resulted conflicting cost-effectiveness. For relapsed/refractory MM, BTZ was 
cost-effective in UK (0.9224 to 1.8027GDPPC/LY) and USA (1.1053 or 1.2136 GDPPC/LY) 
when compared to best supportive care. The cost-effectiveness of BTZ for relapsed/
refractory MM was favourable compared to thalidomide in USA (0.5235 GDPPC/LY) 
and dexamethasone (DEX) in Nordic countries. However, the reported conflicting cost-
effectiveness of BTZ relative to LEN/DEX could also result from indirect comparisons 
on survival outcomes. ConClusions: BTZ was cost-effective for MM prior to SCT, 
MM ineligible for SCT, and relapse/refractory MM when compared to conventional 
treatments. However, caution is needed when interpreting the cost-effectiveness 
of BTZ relative to MPT and MPR-R for MM ineligible for SCT or LEN/DEX for relapse/
refractory MM due to the potential bias associated with indirect comparisons.
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objeCtives: An economic evaluation was conducted to investigate the Incremental 
Cost-Effectiveness Ratio (ICER) of cetuximab in combination with FOLFIRI versus 
FOLFIRI, between three cohorts of the CRYSTAL study, and determine if the cost- 
effectiveness improves when treatment is stratified to patients with the genetic 
biomarkers, KRAS wild-type and RAS wild-type (wt) Methods: From the CRYSTAL 
study, Individual Patient Data (IPD) was obtained from Merck Serono Biostatistics 
department. It was categorised into the three cohorts: the Intention To Treat (ITT) 
population and the two subgroups KRAS wild-type and RAS wild-type. Survival 
analysis was conducted on this data using R studio. Adverse events and resec-
tion rates were also obtained for the cohorts. NHS acquisition costs for cetuximab 
were used. A Merck Serono Cost Utility Model was then re-engineered to economi-
cally evaluate the three cohorts for comparison. Results: From this analysis, the 
deterministic base case ICER, cost per Quality Adjusted Life Year (QALY) gained, 
results are £130,929 in the ITT, £72,053 in the KRAS wt and £44,184 in the RAS wt 
cohorts. ConClusions: From these results, it can be concluded that based on the 
data from the CRYSTAL study, stratification of patients by genetic biomarker KRAS 
wt and RAS wt does improve the cost effectiveness of cetuximab plus FOLFIRI versus 
FOLFIRI alone. The RAS wt cohort had the lowest ICER and is therefore the most cost 
effective of the three groups.
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objeCtives: To evaluate the cost-effectiveness of primary and secondary proph-
ylaxis (PP & SP) with pegfilgrastim, lipegfilgrastim, and with 6-day filgrastim/
lenograstim for chemotherapy-induced febrile neutropenia (FN) in patients with 
stage II and III breast cancer (BC) in Greece. Methods: A Markov model containing 
a decision tree was locally adapted to estimate outcomes from payer perspective. 
The analysis was conducted for a lifetime horizon across three different chemo-
therapy schemes (TC, FEC-D and AC-T). Clinical inputs, such as baseline FN risk, 
efficacy of granulocyte colony-stimulating factors (G-CSFs), mortality, effect of FN 
on relative dose intensity were extracted from published studies. Direct medical 
costs (2015 EUD) for drug acquisition, administration and FN management were 
considered in the model. The outcomes were FN events avoided and incremental 
cost-effectiveness ratio (ICER) per FN event avoided. Results: PP with pegfilgrastim 
was associated with fewest FN events (calculated by combining FN risk with the 
efficacy of G-CSFs: 0.110, 0.100, 0.127 for TC, AC-T, FEC-D, respectively) followed by 
PP with lipegfilgrastim (0.160, 0.146, 0.186 for TC, AC-T, FEC-D, respectively) and PP 
